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In the last decade, researchers have identified a novel modeof gene regulation in the form of a family of small RNAs.
In 1993, investigators first identified in C. elegans a small
RNA, lin-4, which affected developmental timing by forming
a duplex with the 3=UTR of another gene, lin-14, thus
preventing lin-14 translation.1 The identification of lin-4
represented the first small RNA-regulating target mRNA
expression. In 2000, investigators identified another small
RNA let-7 that regulated the gene let-4; however, unlike
lin-4, let-7 was conserved across among several species.2
Both lin-4 and let-7 seemed critical to normal cell differen-
tiation.3 Since this initial discovery, many small RNAs have
been identified as potential regulators of gene expression and
have been termed microRNAs (miRNAs, mirs). MiRNAs are
a family of small noncoding RNAs (approximately 21–25
nucleotides (nt) long) expressed in many organisms, includ-
ing animals, plants, and viruses. MiRNAs originate from
stem-loop precursors and are candidates for the regulation of
both translation and mRNA degradation by base pairing to
complementary sites of target mRNA.4 To date, several
hundred miRNAs have been identified in animals, plants and
viruses, but the biological function has only been identified in
a few miRNAs.5 The biological functions and mechanisms by
which miRNAs are regulated remain poorly understood.
A single miRNA may bind to and regulate several target
mRNAs, whereas several miRNAs may bind and regulate the
same target mRNA.4 Data suggest that miRNAs seem to be
integral to several biological functions, including gene regu-
lation, apoptosis, hematopoetic development, and mainte-
nance of cell differentiation. MiRNAs have been identified in
several human neurodegenerative metabolic diseases and ma-
lignancies.4
MiRNA PROCESSING
MiRNAs may be located in several genomic locations,
such as within introns of protein coding genes or within
introns or exons of noncoding RNAs.6 MiRNAs may exist
either separately from other miRNAs, functioning as individ-
ual transcription units, or in clusters.5 As illustrated in Figure
1, within the nucleus, miRNAs are transcribed as long pri-
mary transcripts by RNA polymerase II into primary miRNAs
(pri-miRNAs), which range from hundreds to thousands of
nucleotides in length.6 While in the nucleus, Drosha, an
RNase III, in conjunction with either DiGeorge syndrome
(critical region gene 8 [DGCR8] in humans) or Pasha (dou-
ble-stranded RNA binding domain dsRBD protein in Dro-
sophila and C. elegans), cleaves both strands of the pri-
miRNA to release a 70- to 100-nucleotide stem loop, termed
the precursor miRNA (pre-miRNA).7 Cleavage by Drosha is
essential for determining the eventual mature miRNA struc-
ture. The pre-miRNA is subsequently exported from the
nucleus to the cytoplasm by the Exportin5/RanGTP.7 Once in
the cytoplasm, a second RNase III termed Dicer, in conjunc-
tion with a dsRBD, cleaves the pre-miRNA, releasing an
approximately 22-nucleotide RNA duplex (mature miRNA
and its complement miRNA*).8 Only one strand of the
miRNA/miRNA* duplex is released to enter the protein
complex of miRNA-containing ribonucleoprotein particles
(miRNPs), and the other strand is degraded.6 MiRNPs guide
miRNAs to the target RNA to regulate protein expression by
either translational inhibition or mRNA degradation.8
MiRNAs bind to the 3=UTR complementary sequences
of target RNA, and the degree of complementary pairing
results in mRNA degradation and/or translational repression.9
Investigators initially identified the first eight bases of
miRNA starting from the 5= end (termed the miRNA seed) as
important and sufficient for the miRNA–mRNA interaction.10
However, investigators suggest that mechanisms for targeting
may be much more complicated.11
MICRORNA IN HUMAN CANCERS
Dysregulation of miRNAs may result in alteration in
biological functions relevant to certain malignancies. Our
current understanding of miRNA function in cancer is mini-
mal.5 Epigenetic alterations including DNA methylation and
somatic gene alterations are potential candidates for mecha-
nisms of regulation.4 The observation that many miRNAs are
located within genomic regions relevant to carcinomas sug-
gests that miRNAs function as either oncogenes or tumor
suppressors.5 Researchers first identified a link between
miRNA expression and human malignancy with the observa-
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tion that there was a downregulation or deletion of miRNAs
mir-15-a and mir-16-1 in locus 13q14 in patients with B-cell
chronic lymphocytic leukemia (CLL).12 More than 50% of
cases of CLL can be attributed to a deletion at 13q14.5 Since
that discovery, researchers have identified abnormal expres-
sion of miRNAs in several types of malignancies, including
CLL, colorectal neoplasia, Burkettt’s lymphoma, large-cell
lymphoma, breast cancer, lung cancer, and hepatocellular and
thyroid carcinoma.13–15 Furthermore, initial expression pro-
filing of miRNAs in patient cohorts with different solid
tumors suggests distinct miRNA signature patterns based on
tumor type.3 Investigators have suggested that miRNAs may
be used as biomarkers in the diagnosis, prognosis, and treat-
ment of cancers.
MiRNA IN LUNG CANCER
In 2005, Johnson et al.16 first identified a connection
between miRNA expression and genes relevant to lung can-
cer. The investigators observed an inverse relationship be-
tween let-7 and RAS protein expression in human cancer cell
lines. Furthermore, microarray analysis of human cancerous
tissue demonstrated decreased let-7 expression in lung cancer
but not in adjacent normal lung tissue, colon cancer, or breast
cancer.17 Researchers also identified a correlation between
expression of let-7 and postoperative survival after curative
resection of lung cancers.18 There have been few studies
examining miRNA expression profiling in human lung can-
cer. Recently, Yanaihara et al.4 used microarray analysis to
identify distinct miRNA profiles between lung cancer and
noncancerous tissue. In addition, the investigators identified
five distinct miRNAs that predicted prognosis among patients
with adenocarcinoma.
MiRNAs are a novel family of small RNAs that are
integral to several biological functions and that regulate gene
expression in many human diseases, including malignancies.
The identification of this new layer of gene regulation and the
potential targets may prove important in diagnosis, treatment,
and prognosis in lung cancers.
MiRBase (http://www.sanger.ac.uk/Software/Rfam/mirna)
provides up-to-date access to sequences, names of novel
miRNA genes, and targets.19,20
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